Page 5 - Demo
P. 5
SPEAKER
TOPIC
SESSION
MODERATOR SPEAKER TOPIC
SESSION
MODERATOR SPEAKER TOPIC
SESSION
MODERATOR SPEAKER TOPIC
SPEAKER
TOPIC
周德陽-中國醫藥大學附設醫院
• Neoadjuvant Immunotherapy for Glioblastoma
• Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma
• Difference Between the Application of Adoptive Cellular Therapy for Primary versus Metastatic Tumors
............. 04
............. 04
• Immunotherapy for CNS Metastatic Tumors
Hot Topic: Modifiable Host Factors and Immune Response
劉妙真 陳怡文-林口長庚紀念醫院
• Impact of Obesity on Immunotherapy: Both the Good and the Bad
• Diet and physical activity alter immunity and the tumor microenvironment
National Cancer Institute Update
王正旭
柯博升-台灣大學醫學院附設醫院
• Real-world Data of Cancer Immunotherapy in Taiwan
............. 04
............. 04
Combination Phase 1-2 Clinical Trials & Update on Combinations
趙祖怡 吳教恩-林口長庚紀念醫院
• Clinical activity of BEMPEG plus NIVO in previously
............. 04
............. 04
............. 04 untreated patients with metastatic melanoma: updated results
from the phase 1/2 PIVOT-02 study
• Novel Combination: IL-2 Combination
• A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma
謝燿宇-衛生福利部雙和醫院
• Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer– Final Results of the phase II AVETUX trial (AIO-KRK-0216)
• Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma who progressed on prior immune checkpoint inhibitor
............. 04 ............. 04
6
.............
04
............. 04
............. 04
............. 04
